SecuritySGEN / Seattle Genetics, Inc.
InstitutionNational Planning Corp
Shares0
Value $ 0

National Planning Corp closes passive position in SGEN / Seattle Genetics, Inc.

February 14, 2018 - National Planning Corp has filed a 13F-HR form disclosing ownership of 0 shares of Seattle Genetics, Inc. (NASDAQ:SGEN) with total holdings valued at $0 USD as of December 31, 2017. National Planning Corp had filed a previous 13F-HR on November 13, 2017 disclosing 92,555 shares of Seattle Genetics, Inc. at a value of $5,363,000 USD. This represents a change in shares of -100.00 percent and a change in value of -100.00 percent during the quarter.

Other investors with closed positions include Tourbillon Capital Partners, L.P., Sabby Management, LLC, EcoR1 Capital, LLC, Credit Agricole S A, and MUFG Americas Holdings Corp.

Seattle Genetics, Inc. has declared a standard industrial code (sic) of 2836 which is the "Biological Products, Except Diagnostic Substances (Biotech)" industry. National Planning Corp's top industries are "Automotive Dealers And Gasoline Service Stations" (sic 55), "Home Furniture, Furnishings, And Equipment Stores" (sic 57), and "Fabricated Metal Products, Except Machinery And Transportation Equipment" (sic 34).

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2017-12-31 13F-HR SEATTLE GENETICS COM 812578102 0 -100.00 0 -100.00
2017-09-30 13F-HR/A-1 SEATTLE GENETICS COM 812578102 53.31 94,430 -14.92 5,138 -11.34 -883 226 3.90
2017-09-30 13F-HR SEATTLE GENETICS COM 812578102 92,555 5,363
2017-06-30 13F-HR SEATTLE GENETICS COM 812578102 57.70 110,990 -0.85 5,795 -18.07 -55 -1,223 -17.29
2017-03-31 13F-HR SEATTLE GENETICS COM 812578102 61.59 111,940 -1.06 7,073 4.21 -74 360 5.30
2016-12-31 13F-HR SEATTLE GENETICS COM 812578102 59.86 113,140 -2.75 6,787 -2.33 -191 29 0.42
2016-09-30 13F-HR SEATTLE GENETICS COM 812578102 54.12 116,335 -0.44 6,949 22.58 -28 1,308 23.07
2016-06-30 13F-HR SEATTLE GENETICS COM 812578102 41.06 116,845 -3.63 5,669 39.12 -181 1,775 43.55
2016-03-31 13F-HR SEATTLE GENETICS COM 812578102 32.73 121,245 -3.44 4,075 1.90 -141 217 5.43
2015-12-31 13F-HR SEATTLE GENETICS COM 812578102 38.06 125,560 -5.51 3,999 -32.04 -279 -1,606 -27.30
2015-09-30 13F-HR SEATTLE GENETICS COM 812578102 44.65 132,885 0.44 5,884 -1.19 26 -97 -1.63
2015-06-30 13F-HR SEATTLE GENETICS COM 812578102 40.01 132,300 -3.39 5,955 24.24 -186 1,348 28.12
2015-03-31 13F-HR SEATTLE GENETICS COM 812578102 16,092.50 136,940 -13.22 4,793 -99.91 -335,690 -4,732,787 -93.29
2014-12-31 13F-HR SEATTLE GENETICS COM 812578102 16,092.89 157,800 2.94 5,073,270 92,410.39 72,418 4,995,368 91,089.86
2014-09-30 13F-HR SEATTLE GENETICS COM 812578102 153,300 5,484

Related SEC Filings

SGEN / Seattle Genetics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) SEATTLE GENETICS INC /WA (Name of Issuer) COMMON STOCK (Title of Class of Securities) 812578102 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

SGEN / Seattle Genetics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) SEATTLE GENETICS INC /WA (Name of Issuer) COMMON STOCK (Title of Class of Securities) 812578102 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

SGEN / Seattle Genetics, Inc. / Capital International Investors - SC 13G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Seattle Genetics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 812578102 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of thi

SGEN / Seattle Genetics, Inc. / Capital International Investors - SC 13G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Seattle Genetics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 812578102 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of thi

SGEN / Seattle Genetics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 14 SEATTLE GENETICS INC COMMON STOCK Cusip #812578102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #812578102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,309,498 Item 6: 0 Item 7: 6,428,347 Item 8: 0 Item 9: 6,428,347 Item 11: 4.

Related News Stories

Genmab's (GNMSF) CEO Jan van de Winkel on Q4 2017 Results - Earnings Call Transcript

2018-02-22 seekingalpha
Good day, everyone and welcome to the Genmab Q4 Report 2017 Conference Call. Today's conference is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results unless this is required by law. (4-0)

Advaxis' Chances: What Can EMA Failures Tell Us About Its Future?

2018-02-19 seekingalpha
In spite of this, the company has achieved a monumental goal of submitting for marketing authorization with the EMA. (194-0)

JF's Core Biotech Buys Edition 1 Volume 3: 2 New Purchases, Plus Thoughts On Portfolio Management And Performance

2018-02-19 seekingalpha
For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio. (279-0)

Merger And Acquisition: What Can Investors Learn From The Seattle Genetics Buyout Of Cascadian?

2018-02-18 seekingalpha
This M&A satisfied 50% of our criteria conducive to a buyout. For one, there is pipeline synergy. (107-1)

BRIEF-Seattle Genetics Announces Expiration Of Hart-Scott-Rodino Waiting Period

2018-02-16 reuters
* SEATTLE GENETICS - ‍REQUIRED WAITING PERIOD UNDER HART-SCOTT-RODINO ACT REGARDING CO‘S PROPOSED ACQUISITION OF CASCADIAN THERAPEUTICS EXPIRED ON FEB 15, 2018​ Source text for Eikon: Further company coverage: (4-0)

LPL Financial signs up 953 NPH advisers and $34.4 billion in assets

2018-02-04 investmentnews
A quarterly report on the trends and ideas that advisers who serve retirement plan sponsors and participants care about. (1-0)

FTLB / First Trust Low Beta Income ETF - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-29 fintel.io
First Trust Low Beta Income ETF (NASDAQ:FTLB) has 10 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 98,351 shares. Largest shareholders include Virtu Financial LLC, Ladenburg Thalmann Financial Services Inc, LPL Financial LLC, Royal Bank Of Canada, National Planning Corp, Cornerstone Wealth Management, LLC, Us Bancorp \de\, IFP Advisors, Inc, UBS Group AG, and Parallax Volatility Advisers, L. (13-0)

MHD / BlackRock MuniHoldings Fund, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-26 fintel.io
BlackRock MuniHoldings Fund, Inc. (NYSE:MHD) has 30 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,197,493 shares. Largest shareholders include Guggenheim Capital Llc, Bank Of America Corp /de/, Morgan Stanley, UBS Group AG, Wells Fargo & Company/mn, Stratos Wealth Partners, LTD., Capital Investment Advisors, LLC, Van Eck Associates Corp, National Planning Corp, and Northern Trust Corp. (164-0)

National Planning Corp - All Holdings - 13F 13D 13G Filings - Fintel.io

2018-01-04 fintel.io
National Planning Corp has disclosed 703 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 1,198,603,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). National Planning Corp's top holdings are SPDR S&P 500 ETF Trust (NYSE:SPY) , Vanguard Total Stock Market Index Fund (NYSE:VTI) , PowerShares QQQ Trust (NASDAQ:QQQ) , iShares Core S&P 500 ETF (NYSE:IVV) , and iShares MSCI EAFE ETF (NYSE:EFA) . (7-0)

Commonwealth adds National Planning firm after LPL buy | Financial Planning

2017-10-26 financial-planning
A father-son firm managing $1.3 billion in client assets opted for Commonwealth Financial Network rather than remaining with National Planning through the transition of its advisors to LPL Financial.




CUSIP: 812578102